Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis
- 1 February 1992
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 15 (2) , 215-221
- https://doi.org/10.1002/hep.1840150208
Abstract
To identify prognostic features and to define the role of liver transplantation in severe autoimmune chronic active hepatitis, findings before and after corticosteroid therapy in 111 patients were correlated with outcome and compared with the findings in 24 patients who had been selected independently for liver transplantation. Patients whose condition deteriorated during corticosteroid treatment were younger (32 ± 3 yr vs. 43 ± 2 yr; p < 0.02) than those who experienced remission, but no individual features predicted outcome. Patients in whom therapy failed required longer durations of continuous treatment than did those who experienced remission (60 ± 14 mo vs. 20 ± 12 mo; p = 0.001). Of 13 patients who did not experience remission within 4 yr, 9 (69%) ultimately deteriorated. Ascites developed more often in those patients whose therapy failed and who died of liver failure than in counterparts who survived (86% vs. 33%). Patients undergoing transplantation were similar to those whose treatment failed, but they died less frequently (8% vs. 56%, p < 0.01). Indeed, the 5-yr survival rate after transplantation was comparable to that of patients who had entered remission (92% vs. 100%). Successive biopsy samples failed to disclose recurrent autoimmune hepatitis after transplantation. Human leukocyte antigens Al, B8 occurred more commonly in patients in whom treatment failed or who underwent transplantation (70% vs. 41%, p < 0.05). We conclude that failure to achieve remission within 4 yr and the human leukocyte antigen Al, B8 phenotype are associated with poor prognosis. Manifestations of liver decompensation, such as ascites, in patients who have been unable to experience remission justify consideration of transplantation. Transplantation improves the survival of patients with features of treatment failure, and it is not associated with recurrent disease. (Hepatology 1991;15:215-221).Keywords
This publication has 40 references indexed in Scilit:
- Frequency and Significance of Antibody to Hepatitis C Virus in Severe Corticosteroid-Treated Autoimmune Chronic Active HepatitisMayo Clinic Proceedings, 1991
- Clinical and prognostic implications of HLA B8 in corticosteroid-treated severe autoimmune chronic active hepatitisGastroenterology, 1990
- The First 100 Liver Transplantations at the Mayo ClinicMayo Clinic Proceedings, 1989
- Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitisGastroenterology, 1988
- Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitisGastroenterology, 1987
- Complete Resolution of Inflammatory Activity Following Corticosteroid Treatment of HBsAg-Negative Chronic Active Hepatitis†Hepatology, 1984
- Natural History, Clinical Features, and Treatment of Autoimmune HepatitisSeminars in Liver Disease, 1984
- Relapse Following Treatment Withdrawal in Patients with Autoimmune Chronic Active HepatitisHepatology, 1983
- CONTROLLED TRIAL OF PREDNISONE AND AZATHIOPRINE IN ACTIVE CHRONIC HEPATITISThe Lancet, 1973
- Controlled Prospective Trial of Corticosteroid Therapy in Active Chronic HepatitisQJM: An International Journal of Medicine, 1971